ESTRO 2024 - Abstract Book

S2109

Clinical - Sarcoma, skin cancer, melanoma

ESTRO 2024

The mean age was 61 years (range, 36-83) with ECOG Performance Status 0-1. The mean sizeof the treated tumor was 6.9 cm (range 2-20). Pathological response was evaluated in 17 patients. In 12patients (70.5%) the tumor was localized in the extremities. 7 (41.2%) patients had been pre-treated with anthracycline-based chemotherapy (mean number of cycles performed 3.5, range 2-4) and 10 (58.8%) were naïve. The radiotherapy technique used was 3D CRT, 2 IMRT, 11 VMAT in 4 patients. All patients followed25 RT sessions in 5 weeks and the mean number of chemotherapy cycles performed was 4.4 (range 3-5). No patients reported acute and late toxicity >/= CTCAE (vers.5.0) grade 3. Six (35.2%) patients reported grade1-2 hematologic toxicity. Of these, three had previously undergone chemotherapy and 5 also underwent hyperthermia during the integrated treatment. All patients (17/17) underwent radical surgery. An R0 resection was obtained in all but one patient (94%). 7 (41.2%) patients achieved a complete pathological response.2/17 (11.8%) patients had post-surgical complications (anastomotic leaks). Five (29.5%) patients had disease progression, (3 local progression and 2 distant metastases). At the time of the analysis, 15/17 (88.2%) patients were alive, 3 with disease and 12 without.

Conclusion:

The combination of RT and Gem in patients with STS is feasible and well tolerated, even after previous chemotherapy or in combination with hyperthermia. It might be more potent than radiation alone in achieving tumor regression and local controlfor high grade STS.

Keywords: neoadjuvant radiochemotherapy

2030

Digital Poster

Impact & usability of virtual reality on emotional wellbeing of sarcoma patients:VR-SARC study

Claire McLeod 1 , Alan Abraham 1 , Leslie Chapman 1 , julie cain 1 , jill scott 1 , Saurabh Vohra 1 , Ray Syed 2 , Ioanna Nixon 1,2

1 beatson, sarcoma, glasgow, United Kingdom. 2 West of Scotland Innovation Hub, cancer, glasgow, United Kingdom

Purpose/Objective:

A diagnosis of sarcoma and going through cancer treatment can have considerable implications on mental & emotional wellbeing.(1) In an ever-adapting technological environment, tools may be utilised to improve overall emotional wellbeing. Challenging diagnoses such as sarcomas gives rise to increased levels of anxiety and impact to mood. In addition, depending on the diagnosis, certain patients can suffer considerable pain levels which may increase overall emotional distress(2). We considered the role of Virtual Reality (VR) modalities and its impact on the emotional wellbeing on patients with sarcoma diagnoses, in addition to considering the usability of such devices.

Material/Methods: